Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 53

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 53
---
 in this prospectus relating to a document filed as an exhibit
is qualified in all respects by the filed exhibit. You should read this prospectus and the documents that we have filed as exhibits
to the registration statement of which this prospectus is a part in their entirety.

<div align='center'>30</div>

We are subject to the informational
requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual
reports on Form 20-F and reports on Form 6-K. The SEC maintains an internet website that contains reports and other information
about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.

We are a “foreign private
issuer” as defined in Rule 3b-4 under the Securities Exchange Act of 1934, or the Exchange Act. As a result, our proxy solicitations
are not subject to the disclosure and procedural requirements of Regulation 14A under the Exchange Act and transactions in our equity
securities by our officers and directors are exempt from Section 16 of the Exchange Act. In addition, we are not required under the
Exchange Act to file periodic reports and financial statements as frequently or as promptly as U.S. companies whose securities are registered
under the Exchange Act. We publish annually an annual report filed on Form 20-F containing financial statements that have been examined
and reported on, with an opinion expressed by, a registered public accounting firm. We prepare our annual financial statements in United
States dollars and in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. If there is any inconsistency
between the information in this prospectus and in any post-effective amendment to the Form F-1 of which this prospectus is a part,
or in any prospectus supplement, you should rely on the information in the post-effective amendment or prospectus supplement, as relevant.
You should read this prospectus and any post-effective amendment or prospectus supplement together with the additional information contained
in documents listed above under the heading “Where You Can Find More Information; Incorporation of Information by Reference.”
The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information
about us, the securities offered under this prospectus, and our other outstanding securities. The registration statement, including the
exhibits, can be read at the SEC’s website mentioned above under “Where You Can Find More Information; Incorporation of Information